If you’re the spouse, dependent or survivor of a veteran who meets certain service-connected disability requirements and you’re enrolled in the Civilian Health and Medical Program of the Department of Veterans Affairs (CHAMPVA), you may choose to participate in Medicare Part D, but should you do it?
Medicare Part D is a prescription drug plan that provides beneficiaries with assistance paying for prescription drugs. To participate, beneficiaries must enroll in one of the many hundreds of Part D plans offered by private companies. If you are currently enrolled in Medicare Part D, you should review your plan each year to ensure you have the plan that best works for you. The annual open enrollment period for Part D runs from Oct. 15 through Dec. 7 each year. During this period, you can switch to a different Medicare Part D plan if your needs change.
Related: Most Military Retirees Will See Medicare Costs Increase in 2027
Should I Participate in the Medicare Part D Drug Plan?
Whether to participate is a personal decision. However, keep in mind that Medicare Part D is considered “other health insurance” (OHI) and will be your primary prescription insurance. After the Medicare Part D plan is billed and you pay your copayments, CHAMPVA will reimburse your copayments up to 100% of the CHAMPVA allowable amount for prescriptions. You will then be responsible for any costs not covered by Medicare and CHAMPVA.
What Are the 2024 Cost Differences Between Medicare Prescription Drug Coverage and CHAMPVA?
|
Medicare Part D Primary |
CHAMPVA Primary |
|
|---|---|---|
|
Cost to enroll (premiums) |
Dependent on plan. The base monthly premium is $41.33 in 2027. |
-0- |
|
Catastrophic cap (maximum out-of-pocket expenses, excluding premiums) |
$2,400 per year (prescription costs only) |
$3,000 per year: All covered prescription and medical expenses apply toward the catastrophic cap. |
|
Prescription copay/deductible |
Dependent on plan. The deductible may not exceed $700 for 2027. |
Retail: 25% copay, $100 family/$50 individual deductible; Meds by Mail: no copays and no deductibles but not available to Part D beneficiaries. |
What Are the Medicare Prescription Drug Plan Deductibles and Copayments for the Standard Drug Benefit, and What Will I Pay?
Your Medicare deductibles and copayments are estimated to be:
- Deductible depends on plan; may not exceed $700 for 2027.
- Catastrophic cap is $2,400 per year (prescription costs only).
Can I Enroll In Medicare Part D And Still Have CHAMPVA For Prescriptions?
Yes. Keep in mind that you may have Medicare Part D enrollment costs. Medicare will be your primary prescription coverage, and CHAMPVA will pay as secondary coverage.
Related: Medicare Open Enrollment
If I’m Enrolled In Medicare Part D, Can I Also Participate in the CHAMPVA Meds by Mail Program?
No. Enrollment in the CHAMPVA Meds by Mail is available only for those who do not have any other prescription drug coverage. If you currently use Meds by Mail, which does not charge copays or deductibles, and elect Medicare Part D, you will no longer be eligible for Meds by Mail and must obtain the prescriptions through the pharmacies authorized by the Medicare Part D plan you choose.
— Additional reporting by Jim Absher
Stay on Top of Your Military Benefits
Not sure what your veteran health care benefits are? Keep up with all the changes and details. Subscribe to Military.com and get all the latest updates straight to your inbox.
Read the full article here

32 Comments
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Uranium names keep pushing higher—supply still tight into 2026.
Nice to see insider buying—usually a good signal in this space.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Uranium names keep pushing higher—supply still tight into 2026.
Good point. Watching costs and grades closely.
Silver leverage is strong here; beta cuts both ways though.
Good point. Watching costs and grades closely.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
I like the balance sheet here—less leverage than peers.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Nice to see insider buying—usually a good signal in this space.
Good point. Watching costs and grades closely.
Production mix shifting toward USA might help margins if metals stay firm.
Good point. Watching costs and grades closely.
I like the balance sheet here—less leverage than peers.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Silver leverage is strong here; beta cuts both ways though.
Silver leverage is strong here; beta cuts both ways though.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Uranium names keep pushing higher—supply still tight into 2026.
Good point. Watching costs and grades closely.
I like the balance sheet here—less leverage than peers.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.